R&D and Medical Affairs, Almirall (US), Exton, PA, USA.
Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Dermatol Ther. 2021 Mar;34(2):e14833. doi: 10.1111/dth.14833. Epub 2021 Feb 21.
Patients' perspectives on actinic keratosis treatments may have an impact on treatment adherence and, therefore, therapeutic outcomes. We performed a systematic review to assess patients' perspectives of topical, field-directed treatments for actinic keratoses. A literature search was conducted, and 14 studies were identified encompassing 4433 patients. Only four studies were focused on face and/or scalp, which are the locations that typically impact patients' quality of life. Four studies were clinical trials. One study utilized a validated patient-reported outcomes (PRO) instrument specifically developed for actinic keratosis. In general, treatment adherence and patient satisfaction were better with shorter-duration treatment regimens such as ingenol mebutate gel. Imiquimod improved quality of life in one study but not in another. No data was available on topical piroxicam. The findings underscore the need for effective and well-tolerated, short-duration topical treatment for actinic keratosis.
患者对光化性角化病治疗方法的看法可能会影响治疗的依从性，从而影响治疗效果。我们进行了一项系统评价，以评估患者对光化性角化病局部、靶向治疗方法的看法。进行了文献检索，确定了 14 项研究，共纳入 4433 名患者。仅有四项研究集中于面部和/或头皮，这些部位通常会影响患者的生活质量。四项研究为临床试验。一项研究使用了专门为光化性角化病开发的经过验证的患者报告结局（PRO）工具。一般来说，与治疗时间较短的治疗方案（如 ingenol mebutate 凝胶）相比，治疗的依从性和患者满意度更高。咪喹莫特在一项研究中改善了生活质量，但在另一项研究中没有。关于外用吡罗昔康尚无数据。这些研究结果强调了需要为光化性角化病提供有效且耐受良好、治疗时间短的局部治疗方法。
